



SAFETY DATA SHEET

SECTION 1: PRODUCT AND COMPANY IDENTIFICATION

Product: SOF-SEAL® COMPONENT B **Part Number:** 4020000
Manufacturer: W. R. Meadows®, Inc. **Address:** 300 Industrial Drive
 Hampshire, Illinois 60140
Telephone: (847) 214-2100 **In case of emergency, dial (800) 424-9300 (CHEMTREC)**
Revision Date: 1/21/2019
Product Use: Low Modulus Sealant

SECTION 2: HAZARDS IDENTIFICATION/EXPOSURE LIMITS

HMIS	HAZARD STATEMENTS
Health	WARNING!
Flammability	Flammable liquid and vapor.
Reactivity	Causes skin, eye, respiratory irritation.
Personal Protection	Suspected of causing genetic defects.
	Causes damage to liver, kidneys, lungs, and blood.
	Harmful if inhaled.
	May be fatal if ingested and enters airway.
	PRECAUTIONARY STATEMENTS
	Use only in well-ventilated areas.
	Avoid breathing vapors/direct contact.
	Store in well-ventilated location.
	Wear appropriate personal protective equipment.
	Keep away from ignition sources.
	Control vapors in confined spaces utilizing mechanical ventilation.



SECTION 3: HAZARDS COMPONENTS

Chemical Name:	CAS Number	% by Weight	SARA 313	Vapor Pressure (mm Hg@20°C)	LEL (@25°C)
1. Xylene	1330-20-7	1-5	Yes	6.6	1.1
2. Petroleum Asphalt	8052-42-4	25-30	No	N/A	N/A
3. Limestone	1317-65-3	25-30	No	N/A	N/A
4. Petroleum Distillate	68477-30-5	5-10	No	N/A	N/A

Under the reporting requirements of Section 313 of Title III of the Superfund Amendments and Reauthorization Act of 1966 (SARA) and 40 CFR Part 372, chemicals listed on the 313 List (40 CFR Part 373.65) are identified under the heading "SARA 313."

N/A = Not Applicable

SECTION 4: EMERGENCY AND FIRST AID PROCEDURES

EYE CONTACT: Flush eyes with water for fifteen minutes. If symptoms persist, seek medical attention.
SKIN CONTACT: Wash affected areas with mild soap and water. Do not use petroleum solvents to remove. If symptoms persist, seek medical attention.
INHALATION: If symptoms persist move victim from exposure source and into fresh air. Treat symptomatically. If symptoms persist, seek medical attention.
INGESTION: Not anticipated to be an exposure route. Dilute by giving victim water or milk to drink. Do not induce vomiting. If vomiting spontaneously occurs keep the victim's head below the hips to prevent lung aspiration. Seek immediate medical attention.
MOST IMPORTANT SYMPTOMS/EFFECTS, ACUTE AND CHRONIC: See Section Eleven for Symptoms/Effects.

SECTION 5: FIRE AND EXPLOSIVES HAZARDS

FLASHPOINT: 130 °F
EXTINGUISHING MEDIA: Water fog, foam, dry chemical, or carbon dioxide.
CHEMICAL/COMBUSTION HAZARDS: Carbon monoxide, carbon dioxide, and incomplete combustion products.
PRECAUTIONS/PERSONAL PROTECTIVE EQUIPMENT: Containers exposed to intense heat from fires should be cooled with water to prevent vapor pressure build-up, resulting in container rupture. Fire fighters should utilize full bunker ensemble when responding to a fire.

SECTION 6: ACCIDENTAL RELEASE MEASURES

SPILL OR LEAK PROCEDURES: Evacuate unnecessary personnel. Dike and contain. Remove/extinguish ignition sources. Product is thick and will not flow quickly when spilled. Wear appropriate personal protective equipment. Place spill materials in sealed/boxed containers for disposal.

SECTION 7: HANDLING AND STORAGE

SAFE HANDLING PROCEDURES: Avoid direct contact. Avoid ignition sources. For exterior use only.
SAFE STORAGE: Keep containers closed when not in use. Store away from ignition sources.

SAFETY DATA SHEET

Date of Preparation: 1/21/19

Page 2 of 3

4020000

SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

Chemical Name:	OSHA				ACGIH			
	PEL	PEL/CEILING	PEL/STEL	SKIN	TWA	TLV/CEILING	TLV/STEL	SKIN
1. Xylene	100 ppm	N/E	N/E	N/E	100 ppm	N/E	150 ppm	N/E
2. Petroleum Asphalt	5 mg/m ³ *	N/E	N/E	N/E	5 mg/m ³ *	N/E	N/E	N/E
3. Limestone+	N/A	N/A	N/A	No	N/A	N/A	N/A	No
4. Petroleum Distillate	N/E	N/E	N/E	N/E	N/E	N/E	N/E	N/E

+: Limestone is in solution. No exposure anticipated unless the product is dried/abraded. *: Asphalt Fumes N/E: Not Established

ENGINEERING CONTROLS: Use with adequate ventilation.

PERSONAL PROTECTIVE EQUIPMENT: Safety glasses, chemical-resistant gloves.

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

BOILING POINT: Not Established	VAPOR DENSITY: >1 (Air=1)	% VOLATILE BY VOLUME: Not Established
EVAPORATION RATE: < 1 (Ether=1)	pH LEVEL: Not Applicable	% VOLATILE BY WEIGHT: 5.00 (Approximate)
WEIGHT PER GALLON: 9.98	PRODUCT APPEARANCE: Black Liquid	VOC CONTENT: 46 g/L
ODOR: Solvent	ODOR THRESHOLD: N/D	MELTING/FREEZING POINT: N/D
FLASH POINT: See Section 5	FLAMMABILITY: N/D	UEL/LEL: N/D
VAPOR PRESSURE: N/D	RELATIVE DENSITY: N/D	SOLUBILITY: N/D
PARTITION COEFFICIENT: N/D	AUTOIGNITION TEMPERATURE: N/D	DECOMPOSITION TEMPERATURE: N/D
VISCOSITY: N/D		<i>N/D: Not Determined</i>

SECTION 10: STABILITY/REACTIVITY

STABILITY: Stable. **HAZARDOUS POLYMERIZATION:** Will not occur.
CONDITIONS AND MATERIALS TO AVOID: Oxidizing agents.
HAZARDOUS DECOMPOSITION PRODUCTS: Oxides of nitrogen/sulfur.

SECTION 11: TOXICOLOGICAL INFORMATION

EYE CONTACT: Move victim from exposure source. Flush eyes with water for fifteen minutes. If symptoms persist, seek medical attention.
SKIN CONTACT: Wash affected areas with mild soap and water. If symptoms persist, seek medical attention.
INHALATION: Exposure to excessive vapor concentrations may result in transient central nervous system depression (headache, fatigue, drowsiness, loss of coordination). Intentional misuse by deliberately concentrating/inhaling vapors may be harmful or fatal. Repeated/prolonged occupational exposures to solvents may cause permanent brain and nervous system damage.
INGESTION: Not anticipated to be an exposure route. Ingestion may cause irritation of the gastrointestinal tract.
SIGNS AND SYMPTOMS: Symptoms of eye irritation include tearing, reddening, and swelling. Symptoms of skin irritation include redness and swelling. Gastrointestinal irritation symptoms include nausea, vomiting, and abdominal discomfort. Symptoms of respiratory irritation include runny nose, sore throat, coughing, chest discomfort, shortness of breath, and reduced lung function. Symptoms of transient central nervous system depression include: headache, fatigue, drowsiness, dizziness, and loss of coordination.
AGGRAVATED MEDICAL CONDITIONS: Pre-existing skin, eye, and respiratory disorders may be aggravated by product exposure.
OTHER HEALTH EFFECTS: Some asphalts and aromatic oils may contain polycyclic aromatic hydrocarbons some of which have been shown to cause skin cancer in laboratory animals under conditions of poor personal hygiene. Intermittent or occasional contact is not expected to present a cancer hazard as long as good personal hygiene measures are followed. Fumes/vapors from these materials may also contain polycyclic aromatic hydrocarbons, so inhalation of these materials should be avoided. Both xylene and aromatic oils have been found to cause the following effects on laboratory animals: liver/kidney effects, blood abnormalities, effects on the spleen, testes, nervous system, adrenals, cardiovascular system, and harm to the fetus. The relevance to humans is unknown.

SECTION 12: ECOLOGICAL INFORMATION

ECOTOXICITY: N/E	DEGRADABILITY: N/E	BIOACCUMULATIVE POTENTIAL: N/E
SOIL MOBILITY: N/E	OTHER ADVERSE EFFECTS: N/E	

SECTION 13: WASTE DISPOSAL INFORMATION

WASTE DISPOSAL INFORMATION: Product will be classified as a hazardous waste (D001). Suitable for fuel blending.

SECTION 14: TRANSPORTATION INFORMATION

HAZARDOUS/NON-HAZARDOUS MATERIAL: Not regulated by domestic ground shipment.
UN NUMBER: None. **HAZARD CLASS:** None. **PACKING GROUP:** None.
UN PROPER SHIPPING NAME: None.
ENVIRONMENTAL HAZARDS: None recognized.
BULK TRANSPORTATION INFORMATION: Not applicable. Product not shipped in bulk configuration.
SPECIAL PRECAUTIONS: None.

SECTION 15: REGULATORY INFORMATION

OTHER REGULATORY CONSIDERATIONS: None.

SAFETY DATA SHEET

Date of Preparation: 1/21/19	Page 3 of 3	4020000
SECTION 16: OTHER INFORMATION		
PREPARATION DATE:	1/21/2019	
PREPARED BY:	Dave Carey	

The information contained herein is based on the data available to us and is believed to be correct. However, we make no warranty, expressed or implied regarding the accuracy of this data or the results to be obtained from the use thereof. We assume no responsibility for injury from the use of this product described herein.
